The above results indicated that the combination of dual targeting of fibrin-fibronectin complexes and MMP-2/9 and MMP-2/9-mediated cleavage allowed iCREKA to achieve tumor cell-specific targeting and membrane penetration. Here, FN1 is linked to neoplasm.